All articles tagged with #lipid nanoparticles
The article discusses how buffer optimization, specifically using mildly acidic, antioxidant-containing buffers like histidine, can significantly improve the room temperature stability of siRNA-lipid nanoparticles by mitigating lipid oxidation and RNA-lipid adduct formation, thereby extending shelf life and maintaining efficacy.
Australian scientists have made a significant breakthrough in HIV research by using mRNA technology with lipid nanoparticles to force the virus out of hiding in infected cells, potentially paving the way for a cure. The team is now preparing for preclinical testing in animals, with human trials possibly years away, and the approach may have broader applications for other diseases.
Researchers have developed a new mRNA delivery method using specialized lipid nanoparticles to make hidden HIV in white blood cells visible, potentially paving the way for a cure, though further research and trials are needed.
Michael J. Mitchell, an associate professor of bioengineering at the University of Pennsylvania, specializes in designing lipid nanoparticles (LNPs) to deliver mRNA inside human cells for potential applications in medicine, including cancer and other diseases. His lab uses microfluidics to create LNPs and has developed a new LNP that mimics a space shuttle to improve mRNA delivery efficiency. They have also successfully targeted the lungs of mice with LNPs and are working on crossing the blood-brain barrier for potential therapeutic applications.
Bioengineers are on the verge of breaking the blood-brain barrier using lipid nanoparticles (LNPs) to deliver messenger RNA (mRNA) for treating neurological conditions like seizures and Alzheimer’s. The University of Pennsylvania researchers have successfully demonstrated the effectiveness of their approach in mice and hope to further test it in various animal models. This breakthrough could pave the way for targeted treatments for a variety of neurological disorders, including brain cancer and strokes, and potentially help cross other barriers in the body.
Scientists at the University of Pennsylvania have developed a new in vitro model of the blood-brain barrier, allowing them to test the delivery of lipid nanoparticles carrying proteins, antibodies, or mRNA therapies into the central nervous system. This breakthrough could lead to novel approaches for treating conditions like traumatic brain injury, stroke, and Alzheimer's, as well as pregnancy-related and retinal diseases. The study's findings, published in Nano Letters, show promise for overcoming the blood-brain barrier and advancing brain-targeted treatments.
Bioengineers are making strides in breaching the blood-brain barrier by developing a method using lipid nanoparticles (LNPs) to deliver mRNA, offering new hope for treating conditions like Alzheimer's disease and seizures. This breakthrough could lead to novel approaches for treating traumatic brain injury, stroke, and Alzheimer's, and the platform is currently tailored for testing a range of LNPs with brain-targeted peptides, antibodies, and various lipid compositions.
Israeli startup Mana.bio has raised $19.5 million in seed financing from investors including Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, and Technion - Israel Institute of Technology. The company aims to address the challenge of delivering genetic medicines to specific cells or organs by developing AI-designed lipid nanoparticles, which can be used to transport mRNA molecules for vaccines or gene therapies.
Researchers have found that enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines can be achieved by adjuvanting both the ionizable lipid and the mRNA. Adjuvants such as lipid nanoparticles have been shown to induce robust T follicular helper cell and humoral responses, leading to increased efficacy of mRNA and protein subunit vaccines. Additionally, the use of heterocyclic lipids in mRNA delivery has been found to activate immune cells through the STING pathway, further enhancing anti-tumor efficacy. The optimization of lipid nanoparticles for mRNA vaccine delivery and the use of adjuvants like ionizable cationic lipid nanoparticles have the potential to improve the immune response and efficacy of mRNA vaccines against COVID-19 and other diseases.
Researchers have developed a new method for delivering CRISPR RNA to the lungs using improved lipid nanoparticles. By synthesizing and screening 720 novel lipids, the authors identified a nanoparticle formulation that achieves moderately efficient editing in the mouse lung after intratracheal delivery of CRISPR RNA-LNPs. This achievement paves the way for therapeutic CRISPR applications in the lung that involve not only gene editing but also gene therapy. The approach should aid the discovery of gene-editing drugs that are effective in treating lung diseases in animal models and, with further optimization, could provide an enabling technology for clinical applications.